INNOVUS PHARMACEUTICALS, INC.: 10-Q filed 2016-11-14

Name: INNOVUS PHARMACEUTICALS, INC.: 10-Q filed 2016-11-14
Creator: INNOVUS PHARMACEUTICALS, INC.
License: https://creativecommons.org/licenses/by/4.0/

What INNOVUS PHARMACEUTICALS, INC. reported in its quarterly report filed 2016-11-14 (fiscal Q3 2016): 32 published measures, 79 facts as tagged in accession 0001654954-16-004030.

This filing

Form: 10-Q (quarterly report)
Filed: 2016-11-14
Fiscal period: fiscal Q3 2016
Accession: 0001654954-16-004030 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All INNOVUS PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2016-09-30	9,059,536	USD
At 2015-12-31	6,347,005	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2016-09-30	9,067,165	USD
At 2015-12-31	6,793,343	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2016-09-30	-7,629	USD
At 2015-12-31	-446,338	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2016-09-30	1,454,545	USD
At 2015-12-31	55,901	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	-4,425,812	USD	92
2016-01-01 to 2016-09-30	-10,341,121	USD	274
2015-07-01 to 2015-09-30	-858,747	USD	92
2015-01-01 to 2015-09-30	-3,224,778	USD	273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2016-01-01 to 2016-09-30	-739,472	USD	274
2015-01-01 to 2015-09-30	-786,012	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2016-01-01 to 2016-09-30	6,565	USD	274
2015-01-01 to 2015-09-30	9,540	USD	273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	1,882,129	USD	92
2016-01-01 to 2016-09-30	3,127,112	USD	274
2015-07-01 to 2015-09-30	179,744	USD	92
2015-01-01 to 2015-09-30	560,069	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2016-01-01 to 2016-09-30	2,294,681	USD	274
2015-01-01 to 2015-09-30	940,870	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2016-01-01 to 2016-09-30	-156,565	USD	274
2015-01-01 to 2015-09-30	-12,816	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2016-09-30	-25,775,716	USD
At 2015-12-31	-15,434,595	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2016-09-30	32,235	USD
At 2015-12-31	35,101	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	-2,244,076	USD	92
2016-01-01 to 2016-09-30	-3,904,362	USD	274
2015-07-01 to 2015-09-30	-653,836	USD	92
2015-01-01 to 2015-09-30	-2,763,930	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2016-09-30	3,061,404	USD
At 2015-12-31	446,719	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	3,727,168	USD	92
2016-01-01 to 2016-09-30	6,000,752	USD	274
2015-07-01 to 2015-09-30	473,360	USD	92
2015-01-01 to 2015-09-30	744,726	USD	273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2016-09-30	4,220,862	USD
At 2015-12-31	2,631,611	USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

Period	Value	Unit	Days
At 2016-09-30	549,368	USD
At 2015-12-31	549,368	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2016-09-30	5,402,000	USD
At 2015-12-31	5,300,859	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2016-09-30	30,875	USD
At 2015-12-31	83,097	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	4,126,205	USD	92
2016-01-01 to 2016-09-30	7,031,474	USD	274
2015-07-01 to 2015-09-30	833,580	USD	92
2015-01-01 to 2015-09-30	3,323,999	USD	273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2016-09-30	396,772	USD
At 2015-12-31	254,443	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	43,775	USD	92
2016-01-01 to 2016-09-30	47,667	USD	274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2016-09-30	104,164,880	shares
At 2015-12-31	47,141,230	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2016-09-30	25,663,922	USD
At 2015-12-31	14,941,116	USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

Period	Value	Unit	Days
At 2016-09-30	412,284	USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

Period	Value	Unit	Days
At 2016-09-30	5,401,571	USD
At 2015-12-31	5,300,859	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	1,779,048	USD	92
2016-01-01 to 2016-09-30	4,012,357	USD	274
2015-07-01 to 2015-09-30	650,539	USD	92
2015-01-01 to 2015-09-30	2,948,413	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2016-01-01 to 2016-09-30	9,431	USD	274
2015-01-01 to 2015-09-30	24,943	USD	273

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	178,082	USD	92
2016-01-01 to 2016-09-30	513,767	USD	274
2015-07-01 to 2015-09-30	147,429	USD	92
2015-01-01 to 2015-09-30	387,011	USD	273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	-2,181,736	USD	92
2016-01-01 to 2016-09-30	-6,436,759	USD	274
2015-07-01 to 2015-09-30	-204,911	USD	92
2015-01-01 to 2015-09-30	-460,848	USD	273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2016-01-01 to 2016-09-30	51,304	USD	274
2015-01-01 to 2015-09-30	123,372	USD	273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2016-01-01 to 2016-09-30	-142,329	USD	274
2015-01-01 to 2015-09-30	-45,245	USD	273

Inspect the source

Entity: INNOVUS PHARMACEUTICALS, INC. / CIK 0001411879
Captured: 2026-09-22 19:47 UTC
SEC response SHA-256: e77a101a672b8634c33f41442578c32e719835a043b28e20b379158f9e2f8bab

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001411879.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))